Table 1.
Baseline demographic and clinical characteristics of the 44 rheumatoid arthritis patients enrolled in the study.
| Characteristics | MTX group | TGTS group | MTX + TGTS group |
|---|---|---|---|
| (n = 15) | (n = 14) | (n = 15) | |
| Age (SD), years | 53.7 (14.2) | 54.1 (14.0) | 55.5 (13.0) |
| Women, n (%) | 28 (80%) | 29 (82.8%) | 28 (80%) |
| Weight (SD), kg | 59.9 (10.1) | 60.3 (11.0) | 61.1 (10.7) |
| Smoking history (SD), years | No | No | No |
| DAS28 (SD) | 5.91 (1.34) | 6.12 (1.23) | 6.07 (1.27) |
| Duration of RA (SD), months | 70.9 (92.8) | 63.7 (89.3) | 56.6 (93.1) |
| Morning stiffness (SD), minutes | 97.8 (63.8) | 104.7 (57.5) | 111.4 (60.0) |
| Anti-CCP positivity, n (%) | 27 (77.1) | 29 (82.8) | 28 (80) |
| RF positivity, n (%) | 28 (80) | 27 (77.1) | 30 (85.7) |
| TJC (SD), n | 14.7 (6.0) | 15.3 (7.0) | 15.9 (6.1) |
| SJC (SD), n | 10.6 (6.5) | 10.6 (6.5) | 11.4 (7.9) |
| CRP (SD), mg/L | 33.3 (28.7) | 31.7 (33.2) | 38.0 (25.5) |
| ESR (SD), mm/h | 54.3 (26.1) | 51.7 (24.4) | 57.0 (27.2) |
| Visual Analogue Score (VAS) evaluated by the patients for pain (SD), mm | 69.0 (18.4) | 70.6 (23.4) | 71.9 (22.5) |
| The patient's global health status assessment of disease (SD), mm | 67.7 (23.7) | 65.0 (25.3) | 68.4 (19.9) |
| The physician's global health status assessment of the patient of disease (SD), mm | 63.2 (22.2) | 61.8 (20.2) | 64.0 (24.6) |
| HAQ (SD) | 1.50 (0.53) | 1.74 (0.77) | 1.73 (0.60) |
Data are presented as mean (SD) or n (%). DAS28,28-joint count Disease Activity Score; Anti-CCP, anti-cyclic citrullinated peptide antibody; RF, rheumatoid factor; TJC, tender joint count; SJC, swollen joint count; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire.